Iterum Therapeutics plc (NASDAQ:ITRM) Short Interest Up 8.3% in November

Iterum Therapeutics plc (NASDAQ:ITRM) saw a large growth in short interest during the month of November. As of November 15th, there was short interest totalling 2,740,000 shares, a growth of 8.3% from the October 31st total of 2,530,000 shares. Based on an average daily volume of 2,480,000 shares, the days-to-cover ratio is currently 1.1 days. Approximately 10.3% of the company’s shares are sold short.

Institutional Investors Weigh In On Iterum Therapeutics

A hedge fund recently bought a new stake in Iterum Therapeutics stock. XTX Topco Ltd bought a new stake in Iterum Therapeutics plc (NASDAQ:ITRM) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 33,040 shares of the company’s stock, valued at approximately $36,000. XTX Topco Ltd owned about 0.15% of Iterum Therapeutics as of its most recent filing with the Securities and Exchange Commission. 9.21% of the stock is currently owned by hedge funds and other institutional investors.

Iterum Therapeutics Stock Performance

Shares of Iterum Therapeutics stock traded up $0.37 during trading hours on Monday, hitting $2.39. The company’s stock had a trading volume of 2,245,366 shares, compared to its average volume of 968,901. The stock has a market cap of $65.76 million, a price-to-earnings ratio of -1.10 and a beta of 2.25. Iterum Therapeutics has a twelve month low of $0.81 and a twelve month high of $2.42. The firm has a fifty day moving average of $1.31 and a 200-day moving average of $1.26.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target on shares of Iterum Therapeutics in a research report on Tuesday, September 10th.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.